INTRODUCTION
Fluoroquinolones are very potent antimicrobial agents with an excellent oral bioavailability reaching serum drug concentrations equivalent to intravenous administrations. They are broad-spectrum antibiotics with an antibacterial activity against Gram-positive as well as Gram-negative bacteria (1, 2) . As a consequence fluoroquinolones are widely and increasingly used for the treatment of bacterial infections not only in the hospital setting but also for the treatment of outpatients. The broad, frequent and world-wide use of the fluoroquinolones and also the frequently inappropriate application of the antibiotics are important factors that drive resistance, which has reached clinically relevant levels in the last decade (3, 4, 5) .
The fluoroquinolones act by directly inhibiting DNA replication via an interaction of the drug with complexes composed of DNA and either of the two target enzymes, DNAgyrase and topoisomerase IV (1, 6) . The molecular mechanisms of fluoroquinolones resistance include two dominant mechanistic categories for all bacterial species studied so far (7, 8) . The activity of multidrug resistance (MDR) efflux pumps act to decrease intracellular fluoroquinolone concentrations (9) and alterations of the drug target by mutations at key sites in the so called quinolone resistance determining regions (QRDR) in genes encoding the DNA-gyrase (gyrA and gyrB) and/or topoisomerase IV (parC and parE) lead to a decreased binding affinity of the quinolones to their respective drug target (10, 11) . More recently mobile genetic elements have also been described, carrying the qnr (12) , qepA (13) or the aac(6')-Ib-cr gene (14) , which confer reduced susceptibility to quinolones in members of the Enterobacteriaceae family. In this study we analyzed a panel of 100 clinical Pseudomonas aeruginosa isolates in respect to the presence of mutations in the QRDRs and the expression of four major efflux pumps in a subset of these. We furthermore introduced the most dominant mutations in the QRDR into the susceptible P. aeruginosa reference strain PA14 and inactivated the efflux regulator-encoding genes nfxB, mexR and mexZ as well as the oxidoreductase mexS with the aim to generate mutants that overexpress the MexCDOprJ, MexAB-OprM, MexXY and MexEF-OprN efflux pump, respectively. The results of this study implicate that there are additional yet unknown mechanisms that contribute to increased ciprofloxacin MIC levels in clinical P. aeruginosa isolates that go beyond mutations in the QRDRs and overexpression of the MexAB-OprM, MexCD-OprJ, MexEF-OprN and/or MexXY-OprM efflux pumps. (Table S1) , from overall 90 individuals, 24 of whom were cystic fibrosis patients. A maximum of two isolates per patient were analyzed in this study only when both isolates clearly differed in their antibiotic resistance profile. Antibiotic resistance profiles (Table S1 ) were determined using a VITEK 2 system (bioMérieux).
MATERIALS AND METHODS

Bacterial
Pyrosequencing. To extract DNA for pyrosequencing, 500 µl of an overnight culture were harvested and lysed for 15 min at 95 °C in 100 µl lysis buffer (0,25 % (m/v) SDS, 50 mM NaOH). After addition of 900 µl dH 2 O, 2 µl was used as a PCR template.
To identify mutations at amino acid position 83 and 87 in gyrA and position 87 in parC a pyrosequencing assay was established. Amplification was performed as described by Doostzadeh et al. (15) using a 24-mer universal biotinylated primer (UBP) adopted from Royo et al. (16) . All primers used in this study are shown in Table S2 . Sequencing primers were designed with Primer3 (17) to anneal 3 bp upstream (gyrA) or 5 bp upstream (parC) from the SNP. Pyrosequencing was performed on a PSQ 96MA pyrosequencer (Pyrosequencing AB) with PyroMark gold chemistry (Qiagen) as described in Royo et al. (16) .
Sanger sequencing. To identify mutations in gyrB and parE the QRDRs of both genes were amplified with primers gyrBfp4, gyrBrp4, parEfp3 and parErp3 (Table S2) . PCR The primers were adopted from Tomás et al. (18) , sequences are listed in Table S2 .
Gene expression was calculated using the ∆∆ Ct method and a standard curve to measure the PCR efficiency. All results were normalized to the expression of the housekeeping gene rpoD of the same clinical isolate and calibrated relative to P. aeruginosa PA14. According to Cabot et al. (19) isolates with a mexA expression of ≥3-fold were regarded as positive, whereas values between 2-and 3-fold were regarded as borderline expression. An overexpression of mexC, mexE and mexX of ≥10-fold was regarded as positive, an overexpression of 5-to 10-fold as borderline expression. Genetic manipulations. To generate mutations of gyrA, gyrB and parC as well as gene knockouts of nfxB, mexR, mexS and mexZ in an isogenic background, the P. aeruginosa strain PA14 was used. Mutagenesis was carried out by homologous recombination using the pEX18Ap plasmid (20) and approximately 1000 bp long mutagenic fragments created by overlap extension PCR as described previously (21) . To generate knockout mutants the 500 bp upstream and downstream regions of the gene of interest were amplified using overlapping primers. All primers are listed in Table S2 . Mutant candidates were identified by replica plating on LB agar plates with appropriate antibiotic concentrations and further analyzed by PCR and Sanger sequencing to verify the mutation. The antibiotic resistance profile of all mutants was determined in MuellerHinton broth as described previously (22) .
Cloning of gyrA and complementation of clinical isolates. To complement gyrA mutations in clinical isolates with the wildtype gene, gyrA was amplified from the PA14 chromosome with primers gyrAFPSacI and gyrARPSacI and cloned into the SacI restriction site of plasmid pME6032 (23) yielding plasmid pME::gyrA. The correct insertion and sequence was verified by Sanger sequencing using primers gyrAseqF, gyrAseqR, pMEseqF and pMEseqR. Complementation was performed as follows: Each isolate was grown over night at 37 °C and 180 rpm in 4 ml LB broth. 1.5 ml of these cultures were centrifuged, washed three times with 1 ml 0.3 M sucrose and resuspended in 100 µl 0.3 M sucrose. 500 ng of the plasmid pME::gyrA and 50 µl of the cell suspension were used for electroporation. The cells were plated on LB agar plates supplemented with 100 µg/ml tetracycline. Ciprofloxacin minimal inhibitory concentration (MIC) of isolates containing pME::gyrA with and without the addition of 1mM IPTG was determined using Etest stripes (bioMérieux) on LB agar plates supplemented with 100 µg/ml tetracycline. Results were recorded after 24 h of growth at 37 °C. accordance with several previous studies (25, 26, 27, 28, 29, 30, 31) , the most frequently observed mutation was within the QRDR of gyrA, with the T83I being the dominant mutation, whereas mutations in gyrB were less frequent (30, 32, 33) . Here, the majority of mutations were found at amino acid positions 466 to 468, however we also found two isolates with an I529V mutation which to our knowledge has not been described previously. Two mutations within the QRDR of parC were detected in our panel of 100 clinical isolates (S87W and S87L) and overall only three mutations were present in parE (one M437I and two A473V). The majority of clinical isolates harbored either a singular mutation in gyrA or gyrB or the combination of mutations in gyrA and parC (Fig. 1B) . Fewer isolates exhibited mutations in gyrB in combination with parE and in gyrA in combination with gyrB with and without additional mutations in the QRDR of parC. Single parC mutations were not found in our panel of clinical P. aeruginosa isolates -as also observed in previous studies (28, 33) , two of the isolates harbored a single mutation in parE and in 14 isolates no mutation in the QRDRs were detected.
RESULTS AND DISCUSSION
It has been observed before that highly resistant P. aeruginosa isolates harboring a double gyrA and parC mutation are almost exclusively isolated from non-cystic fibrosis (CF) patients, whereas in isolates from CF patients single mutations within the QRDRs dominate (34, 35, 36) . Interestingly, in accordance with the previous reports 27 of 29 gyrA/parC mutants of this study were isolated from non-CF patients. It has been suggested that higher drug levels of ciprofloxacin in non-CF patients might account for this phenomenon, since drug levels in CF-sputum were found to be significantly lower than in blood (37) . Although the lower drug concentration levels might select for intermediate resistant strains in distinct niches, it might also indicate that there is a co- Introduction of dominant SNPs within the QRDR of gyrA, gyrB and parC into the susceptible P. aeruginosa reference strain PA14. With the aim to pin-point the contribution of the most frequent mutations within the QRDR of gyrA, gyrB and parC to fluoroquinolone resistance, we introduced the respective SNPs into the fluoroquinolone susceptible reference strain PA14 and measured the resistance profile. Plasmid constructs for allelic exchange were generated for the two SNPs T83I and D87N in gyrA, the three SNPs S466F, S466Y and E468D in gyrB and two SNPs S87L and S87W in parC. Those SNPs were introduced into the reference strain singularly and in various combinations. As shown in Table 1 , the introduction of parC mutations alone did not have an impact on the ciprofloxacin susceptibility, whereas mutations in the QRDR of gyrB or gyrA increased the MIC of ciprofloxacin 8-to 16-fold. Similarly, the introduction of a single parC mutation did not alter the fluoroquinolone susceptibility in E. coli (38) .
The simultaneous introduction of two SNPs within the QRDR of gyrA (T83I and D87N) did not further contribute to ciprofloxacin resistance as compared to the introduction of T83I alone. However, the simultaneous introduction of SNPs in gyrA (T83I) and parC (either S87L or S87W) increased the MIC of ciprofloxacin of the reference strain 256-fold. None of the mutations within the QRDR had an impact on the resistance profile of the parental strain against beta-lactam antibiotics, carbapenems and aminoglycosides (data not shown).
Most clinical P. aeruginosa isolates harboring mutations in the QRDR additionally
express efflux pumps. Mutations in genes encoding the two subunits of DNA-gyrase raised the MIC of ciprofloxacin already 8-to 16-fold in the P. aeruginosa reference strain.
Those gyrA mutants as well as the majority of the clinical isolates harboring relevant mutations in the QRDR of gyrA and/or gyrB exhibited MIC values of ≤2 µg/ml. However, we identified clinical isolates with a singular mutation within gyrA that exhibited MIC values reaching up to 8 µg/ml. The broad MIC range in clinical P. aeruginosa gyrA mutants has been observed in several studies before (34, 39) and although it is tempting to speculate that this can be explained by a differential expression of efflux pumps ( 32, 40) , no clear association of increased MICs against the gyrA mutants and an increased expression of efflux pumps could be demonstrated in previous studies (39, 41, 42) . In the same line, it has been demonstrated for some individual clinical P. aeruginosa isolates that elevated MIC levels of meropenem could not be explained by decreased levels of OprD and/or expression of the MexAB-OprM and MexEF-OprN efflux pumps (43, 44) and it was speculated that other resistance mechanisms yet to be identified might account for the resistance phenotype. We therefore tested whether a differential expression of efflux pumps in those isolates could account for the high MIC values and monitored the expression of four efflux pumps MexAB-OprM, MexCD-OprJ, MexEFOprN and MexXY-OprM in 29 selected clinical isolates. Nine of these isolates did not harbor any mutation in one of the QRDRs, ten isolates harbored a singular gyrA mutation and ten isolates had mutations in gyrA and parC. The quantification of the transcription of the genes encoding the membrane fusion proteins of the pumps (mexA, mexC, mexE and mexX) using qRT-PCR is shown in Table 2 . According to work done by Cabot et al (19) overexpression of mexA of ≥3-fold was regarded as positive, whereas values between 2-and 3-fold were regarded as borderline expression. An overexpression of mexC, mexE and mexX of ≥10-fold was regarded as positive, an (Fig. 3) .
Inactivation of the efflux regulator-encoding genes mexR, nfxB, mexS and mexZ in susceptible P. aeruginosa reference strain. With the aim to pin-point the contribution of overexpression of the MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXY-OprM efflux pumps to fluoroquinolone resistance, we inactivated the respective efflux regulator-encoding genes in the fluoroquinolone susceptible reference strain PA14 and measured the resistance profile. Deletion of the efflux regulator-encoding genes mexR, nfxB and mexZ as well as the oxidoreductase mexS lead to an overexpression of the efflux pump MexAB-OprM by 1.6-fold, the MexCD-OprJ pump by 16-fold, the MexXYOprM pump by 6-fold and the MexEF-OprN pump by 320-fold, respectively (Table 2) .
We also inactivated the efflux regulator-encoding genes in a PA14 strain background in various combinations (∆nfxB-mexZ; ∆mexR-mexS; ∆mexR-mexZ and ∆mexS-mexZ) and also combined the deletion of the four efflux regulator-encoding genes with mutations in the QRDRs (gyrA, gyrB and gyrA/parC). As shown in Table 1 , overexpression of the efflux pumps clearly increased the ciprofloxacin MIC values in the susceptible P. aeruginosa reference strain by 2-to 16-fold. Thereby, inactivation of nfxB and mexS had the most pronounced phenotype. The combined inactivation of various efflux regulator-encoding genes (∆nfxB-mexZ; ∆mexR-mexS; ∆mexR-mexZ and ∆mexS-mexZ) did not lead to further increased MIC levels. This absence of an additive effectmight be explained by antagonistic interactions of efflux pumps during planctonic growth, which was found to occur in nfxB mutants (45) . However, the inactivation of efflux regulator-encoding genes in the PA14 gyrA, gyrB and gyrA/parC mutant background clearly further enhanced the fluoroquinolone resistance level in an additive manner. In accordance to our results the deletion of efflux pumps in resistant P. aeruginosa strains with multiple target alterations has previously been demonstrated to lead to a reduced fluoroquinolone MIC (46) . It might thus be surprising that we did not find a clear correlation of an increased fluoroquinolone MIC value in clinical isolates harboring a particular QRDR genotype with the expression of major efflux pumps.
Mutation within the QRDR of gyrA adds to preexisting isolate specific resistance levels. Although overexpression of efflux pumps further enhanced fluoroquinolone resistance in a QRDR mutant background, we did not find a clear association between expression of efflux pumps and increased fluoroquinolone MIC values in our set of clinical isolates harboring mutations within the QRDRs. We therefore wondered; whether the contribution of a gyrA mutation to the fluoroquinolone resistance level could vary between different isolates. To address this question we cloned the wild-type gyrA gene into the pME6032 vector resulting in vector pME::gyrA and introduced the gene into various clinical isolates in trans. All of those clinical isolates exhibited a gyrA mutation but the MIC values varied from 0.125 -2 µg/ml (Table 3) . We found that the complementation with the wild-type gyrA gene led to a reduction in fluoroquinolone aeruginosa isolates are categorized as susceptible it remains to be shown that it is safe to treat them with fluoroquinolones (49) . The stepwise enrichment of fluoroquinolone resistant mutations has been described previously in several in vitro studies (50, 51, 52) .
Mutants at each step are enriched when drug concentrations fall within a specific range called the mutant selection window (53, 54) . Even antibiotic concentrations below the MIC might select for resistance conferring mutations, as in a recent study, it could be demonstrated that ciprofloxacin concentrations at 1/10 the MIC was sufficient to select de novo fluoroquinolone resistant mutants in E. coli (55) .
Although low level resistance conferred by first-step SNPs within the QRDR does not prevent bacterial eradication in the presence of sufficient levels of a quinolone, they may substantially enhance the number of (secondary) resistant mutants that can be selected from this population. In line with this, it has been demonstrated that deletion of efflux pumps significantly reduces the frequency of emergence of fluoroquinolone resistant mutant isolates (46, 52) . A key to preventing fluoroquinolone resistance in P. aeruginosa MexXY-OprM) with black quarters representing an overexpression of a pump, gray quarters representing borderline expression and white quarter representing wild -type expression levels (according to Cabot et al. 2011 ). The isolates were arranged according to their QRDR genotype (wild type, single mutation in gyrA or simultaneous mutation in gyrA and parC) and their ciprofloxacin MIC.
